

# UCSF

## UC San Francisco Previously Published Works

### Title

Implementation of patient-centered prescription labeling in a safety-net ambulatory care network.

### Permalink

<https://escholarship.org/uc/item/8n49w5p1>

### Journal

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 75(16)

### ISSN

1079-2082

### Authors

Khoong, Elaine C  
Cherian, Roy  
Smith, David E  
[et al.](#)

### Publication Date

2018-08-01

### DOI

10.2146/ajhp170821

Peer reviewed

- 1 **Title:**
- 2 A Case Study in Implementation of a Patient-Centered Prescription Label in a Safety Net
- 3 Ambulatory Network

4 **Abstract**

5

6 **Purpose:** Medication nonadherence negatively impacts patient outcomes and safety.

7 Nonadherence has been attributed to poor understanding of medication label instructions.

8 Research demonstrates that a patient-centered medication label (PCL) can improve adherence

9 and produce safer medication-taking practices. We are not aware of any health system that has

10 pursued widespread adoption of PCL. Our study aimed to describe the factors that impacted PCL

11 adoption at four health-system-run pharmacies within a single publicly-funded safety net

12 healthcare system.

13

14 **Summary:** We used mixed-methods (audit of nearly 9,000 prescription labels and six informant

15 interviews) to determine the rate of PCL-adoption and factors that impacted success. Descriptive

16 statistics were used to analyze data from prescription label audits and the Consolidated

17 Framework for Implementation Research to analyze interview data. Among the four sites, there

18 were differences in the electronic prescribing platform and number of prescribers. Three

19 pharmacies successfully converted >85% of audited prescriptions to PCL-language; one

20 pharmacy converted <25% of prescriptions. Barriers to implementation included pharmacists'

21 reluctance to modify prescriber instructions and inadequate real-time data on conversation rates.

22 Interviewees perceived that leadership and policy directives promoted PCL conversion efforts.

23 Successful pharmacies used adaptable software, had closer communication networks with

24 prescribers, and/or automated PCL conversion.

25

26 **Conclusions:** Local factors affect innovation implementation. We observed greater success in  
27 settings where software could be customized, suggesting that flexible health information  
28 technology supports adoption of evidence-based practices. Collaborative practice between  
29 prescribers and pharmacists also fostered success. Implementation strategies that relied on  
30 repeated individual user actions, rather than automation, were less likely to be successful.

31

32

33

34

35

## 36 **Introduction**

37

### 38 Medication adherence and safety

39

40 Medication adherence for chronic diseases is ~50%.<sup>1</sup> Nonadherence is associated with worse  
41 patient outcomes and increased healthcare costs.<sup>2-4</sup> Studies have documented that complicated  
42 medication regimens, low literacy, and language-related barriers contribute to nonadherence and  
43 compromise patient safety.<sup>5</sup> Improved medication instruction comprehension can improve  
44 adherence and safe medication-taking practices.<sup>6-11</sup>

45

### 46 Patient-centered medication labels

47

48 To this end, the Universal Medication Schedule (UMS) utilizes standardized, patient-centered  
49 language for medication instructions. To promote recall and adherence, these plain-language  
50 instructions are anchored to four time periods: morning, noon, evening, or bedtime. (Appendix 1:  
51 Patient-centered label vs standard medication label.)<sup>12</sup> Standard medication labels have several  
52 possible instructions for medications that can be taken twice daily: take 1 tablet two times daily  
53 or take 1 tablet every 12 hours. Patient-centered labeling that uses the UMS provide only one  
54 option: take 1 tablet in the morning and take 1 tablet in the evening. Similarly, for medications  
55 that can be taken three times a day, providers may ask patients to take 1 tablet three times a day,  
56 every eight hours, or with each meal. UMS-based instructions make explicit to patients that they  
57 should take 1 tablet in the morning, 1 tablet at noon, and 1 tablet in the evening.

58

59 Studies comparing patient-centered prescription drug labels (PCL) with UMS language to  
60 standard labels show its efficacy in improving patient understanding, ability to consolidate  
61 medication regimens, and medication adherence, particularly for patients with low literacy,  
62 limited English proficiency, and complicated medication regimens (medications taken two or  
63 more times daily).<sup>6,12,13</sup> Consequently, the California Board of Pharmacy issued a  
64 recommendation advocating for a PCL.<sup>14</sup>

65  
66 Based on this, the San Francisco Health Network (SFHN) decided to pursue widespread adoption  
67 of PCL. Although we first attempted implementation by modifying *prescribing* behaviors, due to  
68 implementation barriers discussed below, we shifted to *dispensing* medications with PCL at the  
69 four SFHN pharmacy sites. This effort builds on studies that attempted medication dispensing  
70 with PCL at retail pharmacies.<sup>15</sup> In this study, we used the Consolidated Framework for  
71 Implementation Research (CFIR) to identify factors that facilitated and impeded dispensing with  
72 PCL in the SFHN and to identify broader lessons for optimizing implementation of patient-  
73 centered innovations, particularly in safety net systems.

## 74 75 **Methods**

76  
77 **Aim:** This mixed-methods study used an audit of prescription labels and six key informant  
78 interviews to determine the success of PCL implementation and factors that influenced success.

79  
80 **Setting:** This study occurred in a city-and-county-funded, publicly-run integrated safety net  
81 health system (SFHN) that cares for publicly-insured and uninsured patients; the population is

82 low-income and racially/ethnically diverse, with a high prevalence of chronic illness, low health  
83 literacy and limited English proficiency.<sup>16</sup> SFHN has four ambulatory pharmacies serving  
84 distinct populations: jail health (JH), behavioral health (BH), skilled nursing and long-term care  
85 facility (LTC), and an outpatient pharmacy (OP). Although all prescribing is electronic, SFHN  
86 relies on multiple electronic health records (EHRs) across different settings. Each pharmacy has  
87 its own director, who reports to a chief of all ambulatory pharmacies in the San Francisco  
88 Department of Public Health (SFDPH).

89  
90 Implementation strategies: Initial efforts to encourage PCL adoption focused on changing  
91 medication instructions in the prescriber EHR interface by making patient-centered wording the  
92 default option when prescribing medications. Prescribing-centered adoption of PCL was stymied  
93 at multiple levels. First, the EHR vendor failed to enact the requested change at a system level.  
94 Subsequently, local EHR staff attempted to customize the prescribing options to facilitate  
95 patient-centered prescribing. This local work-around resulted in prescribing errors related to  
96 constrained data entry field sizes, and consequently was halted because of medication safety  
97 concerns. Given these barriers, SFHN leadership decided to shift the project's focus from  
98 prescribing with patient-centered language to dispensing medications with PCL. We attempted to  
99 engage the most frequently used commercial pharmacy in our system in this effort but were  
100 unsuccessful. As a result, implementation efforts were limited to dispensing medications with  
101 PCL at the four SFHN-run pharmacies.

102  
103 After both the California Board of Pharmacy and SFDPH leaders prioritized PCL, local leaders  
104 at each of the four sites worked with SFHN leadership to implement PCL. Each SFHN-run

105 pharmacy used various strategies to ensure conversion of standard instructions to UMS-language  
106 and encourage consistent medication dispensing with PCL. These are outlined in Table 1 and  
107 organized by CFIR construct.

108

109 After the initial planning process, most sites engaged stakeholders (prescribers, pharmacists, and  
110 pharmacy technicians) in the conversion process through education sessions and acquisition of  
111 prescriber approval prior to initiating any medication label changes. During the engagement  
112 process, in an effort to address concerns, two sites (LTC and OP) developed policies in their  
113 pharmacy policy committee that resulted in the exclusion of medications (e.g. injectable  
114 medications, medications that the prescribers indicated needed to be taken at specific times) from  
115 conversion to a patient-centered label. Each pharmacy then attempted to convert only  
116 medications determined to be “UMS-eligible” by their policy committee to PCL. Although no  
117 formal policy was created, BH pharmacy leaders also decided that prescriptions with customized  
118 sigs should be excluded from analysis.

119

120 After engagement, each site began execution of their strategy to encourage UMS implementation.  
121 Execution efforts varied widely among the four sites. Some attempted automated approaches  
122 dependent on health technology adaptations (JH and BH) while others used strategies dependent  
123 on individual action (OP).

124

125 Data collection and analysis: Investigators obtained human subjects approval from our  
126 institution’s Committee on Human Research to conduct this study.

127



128 Each site provided data on the characteristics (personnel, number of medications dispensed,  
129 number of prescriptions processed, and pharmacy software) of their site. Pharmacy software  
130 characterization was determined based on publicly available data. Prescription auditing processes  
131 varied at each site. (Table 2) Overall, nearly 9,000 prescription labels were audited.

132  
133 We conducted semi-structured interviews from November 2015 to January 2016 with six key  
134 informants: pharmacy directors from all sites and the chief of ambulatory pharmacies. One  
135 interview (BH) also included a pharmacist lead for implementing PCL. All informants provided  
136 informed consent. The study team used CFIR and its five main domains (intervention  
137 characteristics, outer setting, inner setting, individual, and process) to scaffold the interview  
138 questions.<sup>17</sup> Each interview lasted 30-60 minutes; four interviews were audio-recorded and  
139 transcribed. The policies at one site (JH) proscribed audio-recording, so the interviewer used  
140 extensive written notes.

141  
142 After transcription, we analyzed interviews with qualitative data coding software (Dedoose, Los  
143 Angeles, USA). Two authors (ECK, RC) created codes based on the CFIR framework, separately  
144 coded all transcripts, and discussed coding differences to reach consensus. We chose CFIR  
145 because of its implementation focus and use in other studies in the safety net.<sup>18,19</sup> We also  
146 created project-specific constructs based on an inductive approach.<sup>20</sup> A finalized codebook is  
147 available as Appendix 2.

148

## 149 **Results**

150

151 Implementation Site Characteristics

152

153 Pharmacies varied in size and complexity (Table 3). JH processed the fewest prescriptions and  
154 had the fewest prescribers and pharmacy staff. OP had the largest number of prescribers and  
155 prescriptions processed each day. Both BH and JH used software systems that had fewer  
156 clients/users. At BH, JH, and LTC prescribers and pharmacy staff were co-located allowing for  
157 occasional informal interactions.

158

159 PCL implementation rates

160

161 BH, JH, LTC successfully implemented the UMS for >85% of eligible medications. Only OP  
162 had a persistently low rate of patient-centered prescription labels (Table 4).

163

164 Barriers and facilitators to PCL implementation

165

166 Interviews revealed facilitators and barriers to implementation of PCL within all CFIR domains  
167 (Table 5). There were variations in these factors across sites as well as some common to all sites.

168

169 Variations across sites

170

171 In three key areas, pharmacies with high rates of UMS-implementation differed from the less  
172 successful pharmacy.

173

174 First, adaptable software systems (an outer setting construct) enabled sites (JH, BH) to adopt  
175 PCL by quickly automating printing of medication labels with patient-centered language. More  
176 established software systems were less adaptable thereby inhibiting software facilitated  
177 automation of PCL implementation.

178

179 Sites (JH, LTC) with a circumscribed patient populations and closer communication between  
180 prescribers and pharmacists (inner setting characteristics) achieved more success. Complex sites  
181 (such as OP) with more prescribers, medications, and personnel involved in the prescription  
182 lifecycle (medication prescribing, prescription processing, label printing, and medication  
183 dispensing) were less successful.

184

185 Lastly, sites that automated the conversion process had the most success, regardless of where in  
186 the prescription processing workflow the automation occurred. Often this automation resulted  
187 from software adaptability (JH and BH). The PCL adoption effort at LTC coincided with already  
188 prioritized efforts to move to electronic prescribing, allowing all existing prescriptions to be  
189 manually entered into the EHR using the UMS language.

190

### 191 Barriers across all sites

192

193 One barrier related to the intervention itself was that evidence supporting PCL exists only for  
194 scheduled, ongoing oral medications; therefore pharmacists expressed concerns about extending  
195 UMS language to all medications (e.g. non-oral medications). UMS wording also often did not  
196 fit on prescription labels, especially given competing requirements from the Board of Pharmacy

197 regarding larger label font size. Since pharmacists felt that the Board of Pharmacy was more  
198 aggressively monitoring font size requirements, UMS-wording changes were considered lower  
199 priority changes.

200

201 Individual barriers such as pharmacists' personal experiences and beliefs about professional  
202 responsibilities impacted their attitudes towards PCL. Due to concerns about patient safety and  
203 liability, pharmacists expressed reluctance to change the wording of the prescriber's prescription  
204 despite clinician leaders endorsing PCL.

205

206 All sites had difficulty collecting real-time data to evaluate PCL adoption rates; without this,  
207 implementers were unable to conduct continuous quality improvement. Periodic assessments  
208 were performed only every six to nine months thereby slowing improvement efforts.

209

#### 210 Facilitators across all sites

211

212 All pharmacists agreed that external factors such as the California Board of Pharmacy  
213 regulations and SFHN leadership's commitment facilitated PCL adoption. Creation of a local,  
214 internal policy that formalized prescriber consent of automatic conversion to UMS language was  
215 a crucial early step to support conversion without fear of negative repercussions. Early  
216 engagement of stakeholders (prescribers, pharmacists, pharmacy technicians) also increased  
217 success.

218

#### 219 **Discussion**

220  
221 Implementation of a patient-centered label was a key focus within SFHN because our patient  
222 population has a high prevalence of communication barriers.<sup>21</sup> In low literacy populations,  
223 providers are less effective in enacting crucial elements of patient-centered care such as shared  
224 decision-making; we had also hoped that this patient-centered intervention would help address  
225 health disparities disproportionately experienced by our safety net patient population.<sup>22,23</sup> As an  
226 integrated health system, we hoped that the leadership's commitment would translate into  
227 consistent implementation of PCL and therefore increased opportunities for patient-centered  
228 care. However, we found that challenges from unresponsive health technology vendors and  
229 perspectives on professional boundaries led to mixed success.

230

### 231 Implications for increased adoption of patient-centered drug labels

232

233 Competing requirements for a medication label's real estate impeded UMS adoption. The  
234 simultaneous increased font size requirement from the California Board of Pharmacy made it  
235 difficult to fit all the UMS-recommended language onto prescription labels. Since the Board of  
236 Pharmacy audited pharmacies for font size, that requirement took precedence and posed a barrier  
237 until pharmacists modified the UMS-language while maintaining its core value. For example  
238 whereas twice daily medications in strict UMS-wording would read, "Take 1 tablet by mouth in  
239 the morning and 1 tablet in the evening," pharmacies instead used "Take 1 tablet by mouth in the  
240 morning and evening." This mirrors implementation studies that have demonstrated the need for  
241 intervention flexibility, categorized as "adaptable periphery" using CFIR terminology, while  
242 maintaining the "core components" of the intervention.<sup>24</sup> Furthermore, while the initiative to

243 increase font size is also patient-centered, the tension between these two initiatives demonstrate  
244 the importance for patient-centered efforts to be coordinated.

245

246 EHR limitations forced SFHN to shift focus from prescribing interventions to dispensing  
247 interventions. Prescriber-driven implementation would have mitigated pharmacists' concerns  
248 about professional roles. Despite interest in PCL, prescribers faced significant obstacles:  
249 workflows, large patient panels, and inability to automate UMS-concordant language during the  
250 electronic prescribing process. This finding supports studies that suggest providers' desires to  
251 innovate and provide patient-centered care is not enough; instead, health systems must also have  
252 infrastructure explicitly designed to support innovation and patient-centered care.<sup>25,26</sup>

253

254 Lastly, pharmacists were uncomfortable "owning" the PCL implementation effort and felt  
255 providers should prescribe in patient-centered language to ensure consistency between providers'  
256 verbal instructions and the medication label. Our pharmacists echoed previously described  
257 concerns regarding the liability of changing a transmitted prescription.<sup>27,28</sup> This underscores the  
258 need for bi-directional communication with all stakeholders to avoid resistance. We attempted to  
259 address these concerns through physician champion support and by securing pharmacy  
260 committee approval of PCL adoption before targeting front-line staff behavior change. Future  
261 PCL implementation efforts using dispensing-based strategies must address pharmacists'  
262 concerns of compromising patient safety and job security when translating prescribed  
263 instructions to PCL.

264

265 Implications for adopters of evidence-based, patient-centered innovations

266

267 Pharmacists cited that the California Board of Pharmacy regulations and priorities of SFHN  
268 leaders were key factors encouraging implementation. Prior research has shown that leadership  
269 support and policy changes substantially encourage behavior change.<sup>29,30</sup> Despite these  
270 facilitators, there was still variation in the extent of PCL adoption, suggesting that although  
271 necessary, strong leadership and supportive policies are not sufficient for success in adoption  
272 patient-centered innovations.

273

274 The impact of software adaptability, or lack thereof, was significant. SFHN pursued PCL  
275 dispensing strategies because the initial prescribing attempt was thwarted by the EHR vendor's  
276 unresponsiveness. Once the decision was made to pursue dispensing-based strategies, two sites  
277 (BH, JH) experienced nearly immediate success by directly modify the dispensing software.  
278 Dynamic infrastructure (including software) that responds to a changing environment is an  
279 important facilitator for innovation. Organizations must consider adaptability prior to entering  
280 long-term relationships with vendors and during contract renewals, especially for clinical  
281 software. Healthcare leaders have voiced concern regarding the undue influence of health  
282 technology impeding innovation as well as the need to be wary of assuming that technology will  
283 lead to more patient-centered care.<sup>26,31</sup> As a possible countermeasure, healthcare systems should  
284 consider consolidating purchasing power by utilizing group-purchasing organizations to pressure  
285 vendors to provide customizable software that keeps patients (not billing) at the center of  
286 functionality.

287

288 Sites with smaller networks of personnel and tighter communication had greater success. Smaller  
289 networks made it easier to develop internal policies since high-level decision-making was  
290 consolidated among fewer individuals. Implementation frameworks acknowledge the importance  
291 of the size and proximity of communication networks for adoption of innovation and provision  
292 of patient-centered care.<sup>17,32-34</sup> Collaborative relationships between prescribers and pharmacists  
293 are particularly crucial for patient safety and patient-centered care.<sup>35</sup> Therefore, as many  
294 organizations move towards team-based care model for improved patient-centered care, they  
295 should foster frequent communication among all providers.<sup>34,36</sup>

296  
297 In our study, strategies that involved automation rather than daily vigilance resulted in greater  
298 adoption of PCL. At BH and JH, prescriptions were automatically converted to PCL with a  
299 software modification. At LTC, during the systemic conversion from a paper to electronic  
300 medical record, all prescriptions were entered into the prescriber's EHR using patient-centered  
301 language; therefore future refills also maintained the patient-centered language. In contrast, the  
302 implementation strategy ultimately employed at OP, after the failed prescriber pilot, asked  
303 technicians to manually retype newly received prescriptions using UMS language prior to  
304 printing labels. This strategy required continuous individual effort and resulted in lower  
305 implementation rates. This disparity demonstrates the importance of "default options," a  
306 behavioral economics concept that states when a desired behavior is made the default (rather  
307 than active) choice, the desired behavior is more likely to occur.<sup>37</sup> Implementers must maximize  
308 default options when seeking behavior change.

309



310 Although BH, JH, and LTC were the three sites with the greatest PCL-adoption rates because  
311 they had adaptable software, smaller communication networks, and/or automated processes for  
312 PCL-implementation, these sites are not where patients would have most benefited from PCL.  
313 Patient-centered labels are thought to be most impactful due to increased awareness and  
314 comprehension by the patient or caregivers who directly manage their own medications, which is  
315 not the case in BH, JH, and LTC. BH uses bubble packs, a method of packaging where pills are  
316 packaged in cells based on the time of day to be taken. (An example bubble pack might have 14  
317 bubbles – two bubbles for each day of the week, with pills placed in a morning bubble and a  
318 separate nighttime bubble for each day.) This approach is akin to physically sorting pills in a  
319 manner that UMS spells out in language. Similarly, JH and LTC already have controlled  
320 medication administration; few patients are responsible for their own adherence. Of note, when  
321 patients are discharged from JH and LTC, their discharge medication supply retained the UMS-  
322 language on its labels. Since the LTC utilizes the same EHR as most of the OP clinics, patients  
323 who transition from LTC to OP clinics retained their medication instructions in UMS-language.  
324 In contrast, the OP clinic, where most patients are responsible for their own medication  
325 administration and where PCL could be most impactful, had the least success.

326  
327 This discordance between where implementation is likely to succeed and where it could be most  
328 impactful illustrates both the great promise and great flaw of new interventions. Patient-centered  
329 care has been held as a potentially critical solution to addressing disparities in care and  
330 outcomes.<sup>26</sup> However, when patient-centered efforts rely on health technology that is unevenly  
331 adopted across various systems (and in fact are often more quickly adopted by privileged patients  
332 and healthcare systems) this may increase health disparities instead.<sup>38-40</sup> This underscores the

333 need for research on patient-centered interventions to include diverse, vulnerable patients. New  
334 interventions and strategies to improve quality of care may simply not be equally effective in all  
335 patient populations.

336

### 337 Strengths and limitations

338

339 Although this was a study in a single integrated healthcare system, it has strengths due to the  
340 diversity of patient population, prescribers, and dispensing sites. SFHN is a safety net system  
341 that serves 100,000+ patients with low socioeconomic status and limited English proficiency, as  
342 well as incarcerated individuals, patients with severe mental illness, and long-term care residents.  
343 These populations, and the systems that disproportionately care for them, are under-represented  
344 in research studies. We only included a limited number of leaders as key informants; front-line  
345 pharmacist, prescriber, and patient views will be explored in future studies. As a result of the  
346 barriers encountered with implementing EHR-based strategies for UMS prescribing, this study  
347 focused primarily on pharmacy-based strategies to implement PCL. Another limitation is the  
348 variability in how prescription labels were audited.

349

### 350 Conclusion

351

352 Despite significant barriers, SFHN achieved dramatic improvements in the rates of patient-  
353 centered prescription labels in three of four pharmacies. Adaptable software, tight  
354 communication networks, and automated workflows for adopting PCL increased the likelihood  
355 of PCL implementation success. Based on these findings, there are implications for healthcare

356 systems. Prior to purchasing technology, healthcare systems should recognize that vendors with  
357 many clients might be less likely to provide products adaptable to local patient needs. Patient-  
358 centered care is easier to provide in populations with fewer stakeholders, smaller networks, and  
359 more frequent communication; more research is needed to determine how to provide patient-  
360 centered care across complex and large networks. Automating implementation strategies, rather  
361 than relying on individual actions, can result in greater success when adopting to patient-centered  
362 care strategies. Settings in which patient-centered care may be more likely to successfully  
363 adopted may not be settings that have the most to gain from patient-centered care. We believe  
364 this study identifies key considerations for leaders of safety net healthcare systems and  
365 researchers studying patient-centered innovation implementation in vulnerable populations.

366

367 **References**

- 368
- 369 1. World Health Organization. *Adherence to Long-Term Therapies: Evidence for Action.*;  
370 2003.
- 371 2. Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on  
372 hospitalizations and mortality in heart failure. *J Card Fail.* 2011;17(8):664-669.  
373 doi:10.1016/j.cardfail.2011.04.011.
- 374 3. Hsu KL, Fink JC, Ginsberg JS, et al. Self-reported medication adherence and adverse  
375 patient safety events in CKD. *Am J Kidney Dis.* 2015;66(4):621-629.  
376 doi:10.1053/j.ajkd.2015.03.026.
- 377 4. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication  
378 adherence on coronary artery disease costs and outcomes: A systematic review. *Am J Med.*  
379 2013;126(4):357.e7-357.e27. doi:10.1016/j.amjmed.2012.09.004.
- 380 5. Brown MT, Bussell JK. Medication Adherence: WHO Cares? *Mayo Clin Proc.*  
381 2011;86(4):304-314. doi:10.4065/mcp.2010.0575.
- 382 6. Bailey SC, Sarkar U, Chen AH, Schillinger D, Wolf MS. Evaluation of Language  
383 Concordant, Patient-Centered Drug Label Instructions. *J Gen Intern Med.* 2012:1-7.  
384 doi:10.1007/s11606-012-2035-3.
- 385 7. Wolf MS, Davis TC, Tilson HH, Bass PF, Parker RM. Misunderstanding of prescription  
386 drug warning labels among patients with low literacy. *Am J Heal Pharm.*  
387 2006;63(11):1048-1055. doi:10.2146/ajhp050469.
- 388 8. Persell SD, Osborn CY, Richard R, Skripkauskas S, Wolf MS. Limited health literacy is a  
389 barrier to medication reconciliation in ambulatory care. *J Gen Intern Med.*

- 390 2007;22(11):1523-1526. doi:10.1007/s11606-007-0334-x.
- 391 9. Davis TC, Wolf MS, Iii PFB, et al. Literacy and Misunderstanding Prescription Drug  
392 Labels. *Ann Intern Med.* 2006.
- 393 10. Wolf MS, Curtis LM, Waite K, et al. Helping patients simplify and safely use complex  
394 prescription regimens. *Arch Intern Med.* 2011;171(4):300-305.  
395 doi:10.1001/archinternmed.2011.39.
- 396 11. Machtinger E, Wang F, Chen L, Rodriguez M, Wu S, Schillinger D. A Visual Medication  
397 Schedule to Improve Anticoagulation Control: A Randomized Controlled Trial. *Jt Comm  
398 J Qual Patient Saf.* 2007;33(10).
- 399 12. Wolf MS, Davis TC, Curtis LM, et al. A Patient-Centered Prescription Drug Label to  
400 Promote Appropriate Medication Use and Adherence. *J Gen Intern Med.* 2016.  
401 doi:10.1007/s11606-016-3816-x.
- 402 13. Sahm LJ, Wolf MS, Curtis LM, et al. What's in a label? An exploratory study of patient-  
403 centered drug instructions. *Eur J Clin Pharmacol.* 2012;68(5):777-782.  
404 doi:10.1007/s00228-011-1169-2.
- 405 14. National Council for Prescription Drug Programs. *Universal Medication Schedule White  
406 Paper.*; 2013.
- 407 15. Shrank WH, Parker R, Davis T, et al. Rationale and design of a randomized trial to  
408 evaluate an evidence-based prescription drug label on actual medication use. *Contemp  
409 Clin Trials.* 2010;31(6):564-571. doi:10.1016/j.cct.2010.07.004.
- 410 16. Sarkar U, Schillinger D, López A, Sudore R. Validation of self-reported health literacy  
411 questions among diverse english and spanish-speaking populations. *J Gen Intern Med.*  
412 2011;26(3):265-271. doi:10.1007/s11606-010-1552-1.

- 413 17. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander J a, Lowery JC. Fostering  
414 implementation of health services research findings into practice: a consolidated  
415 framework for advancing implementation science. *Implement Sci.* 2009;4(50):40-55.  
416 doi:10.1186/1748-5908-4-50.
- 417 18. Garg SK, Lyles CR, Ackerman S, et al. Qualitative analysis of programmatic initiatives to  
418 text patients with mobile devices in resource-limited health systems. *BMC Med Inform*  
419 *Decis Mak.* 2016;16(1):16. doi:10.1186/s12911-016-0258-7.
- 420 19. Liang S, Kegler MC, Cotter M, et al. Integrating evidence-based practices for increasing  
421 cancer screenings in safety net health systems: a multiple case study using the  
422 Consolidated Framework for Implementation Research. *Implement Sci.* 2015;11(1):109.  
423 doi:10.1186/s13012-016-0477-4.
- 424 20. Thomas DR. Method Notes A General Inductive Approach for Analyzing Qualitative  
425 Evaluation Data. *Am J Eval.* 2006;27(2):237-246. doi:10.1177/1098214005283748.
- 426 21. Schillinger D, Bindman A, Wang F, Stewart A, Piette J. Functional health literacy and the  
427 quality of physician-patient communication among diabetes patients. *Patient Educ Couns.*  
428 2004;52(3):315-323. doi:10.1016/S0738-3991(03)00107-1.
- 429 22. Aboumatar HJ, Carson KA, Beach MC, Roter DL, Cooper LA. The impact of health  
430 literacy on desire for participation in healthcare, medical visit communication, and patient  
431 reported outcomes among patients with hypertension. *J Gen Intern Med.*  
432 2013;28(11):1469-1476. doi:10.1007/s11606-013-2466-5.
- 433 23. Saha S, Beach MC, Cooper LA. Patient centeredness, cultural competence and healthcare  
434 quality. *J Natl Med Assoc.* 2008;100(11):1275-1285.  
435 doi:10.1016/j.biotechadv.2011.08.021.Secreted.

- 436 24. Kirsh SR, Lawrence RH, Aron DC. Tailoring an intervention to the context and system  
437 redesign related to the intervention: a case study of implementing shared medical  
438 appointments for diabetes. *Implement Sci.* 2008;3:34. doi:10.1186/1748-5908-3-34.
- 439 25. Paulus RA, Davis K, Steele GD. Continuous innovation in health care: Implications of the  
440 Geisinger experience. *Health Aff.* 2008;27(5):1235-1245. doi:10.1377/hlthaff.27.5.1235.
- 441 26. Epstein RM, Fiscella K, Lesser CS, Stange KC. Why the nation needs a policy push on  
442 patient-centered health care. *Health Aff.* 2010;29(8):1489-1495.  
443 doi:10.1377/hlthaff.2009.0888.
- 444 27. Bailey SC, Wolf MS, Lopez A, et al. Expanding the Universal Medication Schedule: a  
445 patient-centred approach. *BMJ Open.* 2014;4(1):e003699. doi:10.1136/bmjopen-2013-  
446 003699.
- 447 28. Kenning C, Protheroe J, Gray N, Ashcroft D, Bower P. The potential for using a Universal  
448 Medication Schedule (UMS) to improve adherence in patients taking multiple medications  
449 in the UK: a qualitative evaluation. *BMC Health Serv Res.* 2015;15:94.  
450 doi:10.1186/s12913-015-0749-8.
- 451 29. Clay-Williams R, Nosrati H, Cunningham FC, Hillman K, Braithwaite J. Do large-scale  
452 hospital- and system-wide interventions improve patient outcomes: a systematic review.  
453 *BMC Health Serv Res.* 2014;14:369. doi:10.1186/1472-6963-14-369.
- 454 30. Barker PM, Reid A, Schall MW. A framework for scaling up health interventions: lessons  
455 from large-scale improvement initiatives in Africa. *Implement Sci.* 2016;11(1):12.  
456 doi:10.1186/s13012-016-0374-x.
- 457 31. Mandl KD, Kohane IS. Escaping the EHR trap - the future of health IT. *N Engl J Med.*  
458 2012;366(24):2240-2242. doi:10.1056/NEJMp1203102.

- 459 32. Greenhalgh, T., Robert, G., Macfarlane, F., Bate, P., & Kyriakidou O. Diffusion of  
460 Innovations in Service Organizations: Systematic Review and Recommendations. *Milbank*  
461 *Q.* 2004;82(4):581–629. doi:doi:10.1111/j.0887-378X.2004.00325.x.
- 462 33. Feldstein AC, Glasgow RE. A Practical , Robust Implementation for Integrating Research  
463 Findings into Practice. *Jt Comm J Qual Patient Saf.* 2008;34(4):228-243.
- 464 34. Bernabeo E, Holmboe ES. Patients, providers, and systems need to acquire a specific set  
465 of competencies to achieve truly patient-centered care. *Health Aff.* 2013;32(2):250-258.  
466 doi:10.1377/hlthaff.2012.1120.
- 467 35. Pontefract SK, Hodson J, Marriott JF, Redwood S, Coleman JJ. Pharmacist-Physician  
468 Communications in a Highly Computerised Hospital: Sign-Off and Action of Electronic  
469 Review Messages. *PLoS One.* 2016;11(8):1-17. doi:10.1371/journal.pone.0160075.
- 470 36. Haidet P, Fecile ML, West HF, Teal CR. Reconsidering the team concept: Educational  
471 implications for patient-centered cancer care. *Patient Educ Couns.* 2009;77(3):450-455.  
472 doi:10.1016/j.pec.2009.09.020.
- 473 37. Smith N, Goldstein DG, Johnson EJ. Choice Without Awareness: Ethical and Policy  
474 Implications of Defaults. *J Public Policy ....* 2013;32(2):159-172.  
475 doi:10.1509/jppm.10.114.
- 476 38. Custodio R, Graham G. Health Information Technology: Addressing Health Disparity by  
477 Improving Quality, Increasing Access, and Developing Workforce. *J Health Care Poor*  
478 *Underserved.* 2016;20(2):301-307.
- 479 39. Jha AK, DesRoches CM, Shields AE, et al. Evidence of an emerging digital divide among  
480 hospitals that care for the poor. *Health Aff (Millwood).* 2009;28(6).  
481 doi:10.1377/hlthaff.28.6.w1160.



482 40. Goldman DP, Lakdawalla DN. A Theory of Health Disparities and Medical Technology.  
483 *Contrib Econ Anal Policy*. 2005;4(1). doi:10.2202/1538-0645.1395.

484

485

486 **Keywords**

487 Medication adherence

488 Patient-centered prescription labeling

489 Implementation

490 Safety-net

491 Health literacy

492

493

494

495 **Key Points**

496 • Pharmacy software adaptability to local customizations impacts how quickly health  
497 systems can adopt innovative approaches to improve medication adherence.

498 • Collaborative care models that involve frequent communication between prescribers and  
499 pharmacists are crucial to quick adoption of new medication adherence technology.

500 • Implementation strategies that automate changes rather than relying on individual actions  
501 are more quickly adopted.

**Table 1: Interventions to Increase Patient-Centered Drug Labeling at Each Pharmacy Site**

CFIR Construct	Intervention	Pharmacy Site			
		Behavioral Health (BH)	Jail Health (JH)	Long Term Care (LTC)	Outpatient Pharmacy (OP)
<b>Outer setting: external policies and incentives</b>	California Board of Pharmacy requires patient-centered labeling				
	SFDPH requires pharmacies to dispense using Universal Medical Schedule (UMS) language				
<b>Process: Planning</b>	Meetings to discuss strategy for conversion to UMS				
	Audit to assess baseline use of UMS language				
<b>Process: Engaging</b>	Encourage prescribers to use UMS language				
	Policy and procedure committee approves pharmacist conversion of instructions to UMS language for “UMS-eligible” medications				
	Collaboration with software vendor to ease UMS conversion				
	Acquire prescriber approval to convert labels to UMS	Prescriber also dispenser			
	Educating dispensers about intervention				
	Educating prescribers about intervention				
<b>Process: Executing</b>	Staff medication review and protocol creation for UMS conversion/exceptions				
	Prescriptions entered in UMS language during roll-out of electronic prescribing software				
	Technicians add/test new UMS shortcut conversion codes				
	Staff rewrite shortcut conversion codes (e.g. BID becomes QAM & QPM)				
	Overnight conversion of short codes to UMS language				
<b>Process: Reflecting and evaluating</b>	Outcomes evaluation				
	Test new workflow				
	Downsize exception list and expand UMS				
	Modify UMS language to fit onto label				

	Executed successfully
	Attempted
	Not attempted or not applicable

**Table 2. Characteristics of data collection process for prescription label audits**

	<b>Pre-implementation data collection</b>		<b>Post-implementation data collection</b>	
<b>SFDPH Pharmacy Sites</b>	Time frame	Analyzed prescriptions (n) <sup>a</sup>	Time frame	Analyzed prescriptions (n) <sup>a</sup>
Behavioral Health (BH)	One week February 2014	All prescription labels without customized sigs (34)	One week August 2015	All prescription labels without customized sigs (32)
Jail Health (JH)	One month March 2008	Prescription labels for patients discharged from JH (80)	One month March 2016	Prescription labels for patients discharged from JH (86)
Long Term Care (LTC)	One month January 2015	Prescription labels for patients discharged from LTC (158)	One month February 2016	Prescription labels for all UMS-eligible medications (612)
Outpatient Pharmacy (OP)	One month March 2015	Prescription labels for all UMS-eligible medications (4317)	One month November 2015	Prescription labels for all UMS-eligible medications (3571)

<sup>a</sup> BH and LTC data were collected by a local pharmacist. JH and OP data were collected by a research team member.

**Table 3. Characteristics of the 4 San Francisco Department of Public Health pharmacies**

	<b>Characteristic</b>				
<b>SFDPH Pharmacy Sites</b>	Personnel	Number of unique medications dispensed	Average # prescriptions processed daily	% of prescriptions UMS- eligible	Characterization of pharmacy software <sup>a</sup>
Behavioral Health (BH)	10 pharmacists 5 technicians 250 prescribers	116 medications	71 prescriptions	100%	Visual Superscript (DAA, Brookline, MA; 500 systems installed)
Jail Health (JH)	3 pharmacists 5 pharmacy techs 10 prescribers	414 medications	43 prescriptions	100%	Jail Information Systems (locally developed)
Long Term Care (LTC)	16 pharmacists 11 pharmacy techs 38 prescribers	722 medications	113 prescriptions	58% (416/722)	QS / 1 (JM Smith, Spartanburg, SC; 6000+ systems installed)
Outpatient Pharmacy (OP)	10 pharmacists 10 pharmacy techs 749 prescribers	670 medications	310 prescriptions	52% (347/670)	Pharmacy 2000 (Parata, Durham, NC; 12000+ systems installed)

<sup>a</sup> Data acquired from <http://www.computertalk.com/buyer/> or company website

**Table 4. Rates of patient-centered labels (PCL) pre- and post-PCL implementation for UMS-eligible prescriptions only.**

<b>SFDPH Pharmacy Sites</b>	<b>Pre-Implementation</b>	<b>Post-Implementation</b>
Behavioral Health (BH)	<b>0%</b> (0 / 34)	<b>94%</b> (30 / 32)
Jail Health (JH)	<b>14%</b> (11 / 80)	<b>99%</b> (85 / 86)
Long Term Care (LTC)	<b>34%</b> (54 / 158) <sup>a</sup>	<b>88%</b> (541 / 612)
Outpatient Pharmacy (OP)	<b>23%</b> (991 / 4317)	<b>23%</b> (835 / 3571)

<sup>a</sup> Data available only for all medications (including non-UMS eligible medications) but acquired only from prescriptions issued for patients discharged from the facility

**Table 5. Key barriers or facilitators to patient-centered drug label adoption at SFDPH pharmacies**

Factor	Short description	Barrier or Facilitator	Example Quote(s)
<b>INTERVENTION</b>			
Evidence strength & quality	There was good evidence to support the UMS but none tied to patient outcomes	Barrier	Until we have outcomes data, I think it's going to be hard...it's a lot of work to do this...You really want to know that you're improving outcomes as a result of it, not just patient understanding...
		Facilitator	There is data to show that it improves people picking up their prescriptions and likely improves adherence... we're definitely aligned with trying to do things that will foster that
Adaptability	The UMS language is long and poses logistic problems but if the UMS is perceived as adaptable, this can be overcome	Barrier	The standard is: take 1 tablet in the morning, take 1 tablet at noon and take 1 tablet in the evening. We consolidated take 1 tablet in the morning, noon, and evening. That fits in our labels, and so that was something that the group.
Complexity	Implementation of the intervention was more complicated than anticipated	Barrier	We also thought it would be relatively easy. How hard is it, right? You're just...modestly changing a sig and you have potentially a pretty significant impact on adherence and outcomes...it ended up being much more difficult than we ever expected that it would be to implement this.
Broad applicability to medications	The UMS does not seem applicable to all meds	Barrier	Some pharmacists... half their medications they feel uncomfortable using UMS. Then, it almost destroys... it because it doesn't really apply if you say, "Oh. Well, this drug maybe that doesn't quite fit," when you start slicing and dicing.
<b>OUTER SETTING</b>			
External policy & incentives	SFDPH pressure and board of pharmacy policy encouraged behavior change	Facilitator	I probably was most aware of it.. when the Board of Pharmacy Law was changed where they actually were going to require it...
		Facilitator	What was helpful for me... the executive team ... made this one of our initiatives to do DPH-wide. There were times I'm ready to go to exec meeting, and I'm going, "Oh, my God! What have we done? I've got to go and report something." Without that... [pressure] ... it could have gotten just lost in the shuffle of all the different things we are doing.
Corporation responsiveness	The willingness of software vendors to accommodate custom requests impacted the ability to implement.	Barrier	Basically, we got no from [electronic prescribing software] and we got no response from the database vendors, and so realizing that that was not going to be a path that was going to be either quick or easy.
		Facilitator	I started working with our EHR in 2009... I've been working with the developer for 5 years... We know them all, and I go to conferences and I talk to him about what's important to us... that informs his next generation development... We see a lot of his development stuff before it happens... He's developed stuff that we'd asked for.
<b>INNER SETTING</b>			
Structural characteristic: broader patient population	Broader diversity of patients (and medications) made broad applicability of the UMS more difficult	Barrier or Facilitator	I think they had an easier time than we did because of the way they dispense their medications, just their more closed network and I think they have more control with the prescriptions that are being given out versus [Outpatient Pharmacy] where we have wider range of patients.
Internal policy	Implementation was more successful once an internal committee had approved the UMS conversions	Facilitator	We actually have created a policy for the pharmacy department on how we will utilize UMS language when dispensing prescription medications from our outpatient pharmacy. We obtained approval from the Pharmacy and Therapeutics Committee to automatically change any directions for use that come in a standard or traditional sig code to the UMS language...That gave staff the authority and they didn't feel like they were overstepping the physician.

Network and communication	Sites with tighter communication between pharmacists and prescribers adopted more quickly	Barrier	As UMS came up again and we actually took initiative to try to implement it here [Outpatient Pharmacy], some of the other issues that started to come up or concerns that started to come up was... for [the] provider... it's one direction and we changed it to another. Is that okay? How is the provider going to know we changed it? So the communication piece between the pharmacy and the provider.
		Facilitator	I think it is definitely easier to implement when you're a specialty pharmacy. Right now, we're working with [only] so many people... but... having the clinical pharmacists all get together and brainstorm like what is actually important versus like an entire system where there are a lot of opinions to be heard really helped narrow it... just 7 people have to get on the same page.
Readiness for change: Leadership Engagement	The commitment of the pharmacy leader to adoption was a facilitator	Barrier	I think partly, it's the leader of the Outpatient Pharmacy who did not buy into this very easily, so that outpatient pharmacy supervisor had her own concern.
		Facilitator	I think what helped was just having a lot of support from...our director
<b>INDIVIDUAL</b>			
Personal beliefs, knowledge, and attitude about intervention	Pharmacists' beliefs about ease of implementation and impact of the UMS on patients (safety, adherence, understanding, autonomy) affected adoption	Barrier	I think the staff still have it in their minds that - why would you want to change somebody's schedule or why would you want to dictate to somebody when to take something
		Facilitator	I felt with our patient population, very low literacy, not stable especially with healthcare coming in and out of the system, I felt UMS would be more of a benefit than versus maybe another healthcare system.
Personal beliefs, knowledge, and attitudes on professional role	Pharmacists' perceptions on their roles and responsibilities affected the UMS success	Barrier	There's always been a lot of hesitation because they feel like they need to write the directions exactly how they're written, and they don't want to stray from what the doctor said even if the doctor's plan is unclear. They put a lot of the pressure on the patient to figure out the directions on their own and just as a protective response, they don't want to stray from what was intended
Personal experiences	An individuals' own experiences w patient care impacts their perceptions on the utility of the UMS	Facilitator	Our clinical pharmacist's primary practice is actually indirect client care in our behavioral health clinics. I think, for them, their decisions are informed by reality of realizing what makes sense to a patient and what helps with compliance.
<b>PROCESS</b>			
Engagement	Engaging members across the implementation spectrum resulted in quicker adoption	Facilitator	There was initially I guess a lot of back and forth and conversation but once they agreed as a group on how to move forward and the fact that they could program their system, it was really quite simple.
Execution: automated changes	Success occurred in areas where changes were automated	Facilitator	Once you changed the labeling... the algorithm, QD if you typed that... which we usually type out once daily, they were all automatically converted... to UMS. Everything automatically converted.
Execution: policy	Internal policy changes provided pharmacists perceived approval from prescribers	Facilitator	So we put in an automatic substitution policy that essentially defined what – how the prescriptions were going to be translated and that ... raised the comfort for the pharmacists dramatically
Evaluation	The ability to measure outcomes quickly was crucial for assessing impact of interventions.	Barrier	The other problem that the Outpatient Pharmacy has is they don't have a way of monitoring it or measuring their success... it has become a quality improvement project... collecting the data... that's a lot of work for them. They have not done a good job of seeing where they are at any one point in time to really try to identify the areas that are continuing to be challenges for them.

**Appendix 1. Examples of Universal Medication Schedule instructions and patient-centered labels (PCL)**

<b>Standard instructions</b>	<b>UMS-based instructions</b>
Take 2 tablets twice a day OR Take 2 tablets every 12 hours	Take 2 tablets in the morning and take 2 tablets at bedtime
Take 1 tablet four times a day OR Take 1 tablet every 6 hours	Take 1 tablet in the morning, 1 tablet at noon, 1 tablet in the evening, and 1 tablet at bedtime
Take 3 tablets daily	Take 3 tablets in the morning OR Take 3 tablets at bedtime
Take 2 tablets three times a day OR Take 2 tablets every 8 hours	Take 2 tablets in the morning, 2 tablets at noon, and 2 tablets in the evening

09/01/2009 Rx# 6607815

**AMOXICILLIN 500MG CAP RANBAXY**

You have 2 refills  
40 pills  
Discard After 09/01/2010  
DR RUTH PARKER, MD

**Take:**  
2 PILLS IN THE MORNING  
2 PILLS IN THE EVENING

Morning 7-9 AM	Noon 11-1 PM	Evening 4-6 PM	Bedtime 9-11 PM
2		2	

NOVA SCRIPTSCENTRAL  
6400 Arlington Blvd Ste. 120  
Falls Church, VA. 22042  
(703)532-0158

NDC# 63304-0655-05  
Rx Only HN

**VICTOR'S DRUGS** 1625 N MARKET BLVD  
SACRAMENTO, CA 95834  
(916) 574-7900

ALL INFORMATION CONTAINED HEREIN IS THE PROPERTY OF THE DRUG MANUFACTURER. FOR THE PATENT FOR WHICH IT HAS BEEN GRANTED.

**JOHNSON, JUDITH** Rx: 06197 1234567  
Refills: 3 Qty:

**1 AZOPT Ophth 1% Susp 10ml AL**  
Alcon Laboratories

**Instill 1 drop in each eye in the morning and 1 drop in each eye in the evening for glaucoma. \*Do not use other eye drops for at least 10 minutes\***

Prescriber: Roger Brown MD Expires: 10/01/10



## Appendix 2. CFIR-based codebook used for analysis

CFIR Construct	Sub-constructs	
Intervention	<ul style="list-style-type: none"> <li>• Evidence strength &amp; quality</li> <li>• Adaptability</li> </ul>	<ul style="list-style-type: none"> <li>• Complexity               <ul style="list-style-type: none"> <li>○ Applicability to medications</li> </ul> </li> <li>• Other unexpected outcomes</li> </ul>
Outer Setting	<ul style="list-style-type: none"> <li>• Peer Influence               <ul style="list-style-type: none"> <li>○ Peer pressure</li> <li>○ Non-Pharm support</li> </ul> </li> <li>• Competing priorities</li> </ul>	<ul style="list-style-type: none"> <li>• External policy &amp; incentives               <ul style="list-style-type: none"> <li>○ State Board of Pharmacy</li> <li>○ San Francisco Department of Public Health</li> </ul> </li> <li>• Corporation responsiveness</li> </ul>
Inner Setting	<ul style="list-style-type: none"> <li>• Structural characteristics               <ul style="list-style-type: none"> <li>○ Medication administration</li> <li>○ Diversity of medications</li> <li>○ Software</li> <li>○ Patient population</li> </ul> </li> <li>• Networks and communication               <ul style="list-style-type: none"> <li>○ Organization size</li> <li>○ Pharmacy-prescriber relations</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Implementation climate               <ul style="list-style-type: none"> <li>○ Internal competing priorities</li> </ul> </li> <li>• Readiness for implementation               <ul style="list-style-type: none"> <li>○ Leadership excitement</li> </ul> </li> <li>• Pharmacist responsibilities</li> <li>• Internal policy</li> </ul>
Individual	<ul style="list-style-type: none"> <li>• Personal beliefs, knowledge, and attitude about intervention</li> <li>• Willingness to be flexible</li> </ul>	<ul style="list-style-type: none"> <li>• Personal beliefs, knowledge, and attitudes on pharmacists' professional role</li> <li>• Personal experiences</li> <li>• Personal competing priorities</li> </ul>
Process	<ul style="list-style-type: none"> <li>• Planning</li> <li>• Engaging               <ul style="list-style-type: none"> <li>○ Involvement in policy development</li> </ul> </li> <li>• Execution               <ul style="list-style-type: none"> <li>○ Prescriber-side</li> <li>○ Policy</li> <li>○ Automated changes</li> <li>○ Education</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Reflection               <ul style="list-style-type: none"> <li>○ Iteration</li> <li>○ Decision-making support</li> </ul> </li> <li>• Evaluation               <ul style="list-style-type: none"> <li>○ Iteration</li> </ul> </li> </ul>